Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist Silexion as it advances its RNAi platform and next-generation therapies targeting KRAS mutations
Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics who has been involved in numerous successful publicly traded bio-pharma companies, will also serve on the Company's audit, compensation, and nominating and corporate governance committees. The Board unanimously approved his appointment, citing his decades of experience in advancing novel cancer therapies from discovery to FDA approval.
Ilan Hadar, Chairman and CEO of Silexion, commented: "We are thrilled to welcome Prof. Peled to our Board of Directors. His unparalleled expertise in cancer biology, stem cell mobilization, and therapeutic development will be invaluable as Silexion continues to advance its pipeline of RNAi-based therapies for difficult-to-treat cancers. Prof. Peled's track record in translating innovative science into impactful clinical outcomes aligns perfectly with our mission to address unmet needs in oncology."
"I am excited to join Silexion at such a pivotal time in its journey," said Prof. Amnon Peled. "The Company's RNAi platform holds tremendous promise for addressing some of the most challenging oncology indications. I look forward to contributing my expertise to help advance Silexion's innovative pipeline and drive meaningful impact for patients."
Prof. Peled's appointment reinforces Silexion's commitment to scientific and strategic excellence as it advances its RNAi platform and next-generation therapies targeting KRAS mutations. His extensive experience in clinical development and regulatory pathways will contribute to Silexion's mission of delivering innovative solutions for patients facing the most challenging cancers. Prof. Peled's appointment also fills its current board vacancy, ensuring Silexion remains in compliance with Nasdaq's listing requirements, including having a fully constituted audit committee.
About Prof. Amnon Peled
Prof. Peled serves as the Director of the Gene Therapy Institute at Hadassah Medical Center in Jerusalem, where his research focuses on cytokine roles in hematopoietic stem cell biology, inflammation, and cancer. Over his 28-year career, he has led groundbreaking research into the chemokine receptor CXCR4, a key player in stem cell mobilization and cancer. Prof. Peled has authored over 120 scientific publications and holds more than 200 patents and patent applications related to therapeutic applications in stem cell biology, immunology, and cancer.
Prof. Peled's contributions to biotechnology include close collaborations with leading Israeli biotech companies such as Biokine Therapeutics, BiolineRX (NASDAQ: BLRX), Gamida Cell, KAHR Medical, and AlonBio. He is the founder of Biokine Therapeutics, AlonBio, and SakuraBio. His leadership in the development of the CXCR4 antagonist BKT140/BL8040 and Gamida Cell's NK and cord blood stem cell expansion technologies has resulted in multiple FDA approvals. Prof. Peled earned his Ph.D. from the Weizmann Institute of Science and conducted postdoctoral research at Harvard Medical School and Millennium Pharmaceuticals, Inc.
About Silexion Therapeutics
Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers.
佩雷德教授是一位全球公认的科学权威，曾参与多家成功上市的生物制药公司，将协助Silexion推动其RNA干扰平台和针对KRAS突变的下一代疗法。
开曼群岛，2024年12月10日 – Silexion Therapeutics Corp.（纳斯达克：SLXN）（"Silexion"或"公司"），一家开发针对KRAS驱动癌症的RNA干扰（RNAi）疗法的临床阶段生物技术公司，今天宣布任命佩雷德教授为独立董事，加入其董事会。佩雷德教授是干细胞生物学、免疫学和癌症治疗领域的全球公认权威，曾参与多家成功上市的生物制药公司，他还将担任公司审计、薪酬、提名和公司治理委员会的成员。董事会全体成员一致批准了他的任命，称赞他在将新型癌症疗法从发现推进到FDA批准方面拥有数十年的经验。
Silexion的董事会主席兼首席执行官伊兰·哈达尔评论道："我们很高兴欢迎佩雷德教授加入我们的董事会。他在癌症生物学、干细胞动员和治疗开发方面无与伦比的专业知识，将对Silexion继续推进其基于RNAi的困难癌症治疗管线具有重要价值。佩雷德教授在将创新科学转化为有影响力的临床结果方面的成功记录，与我们满足肿瘤学未满足需求的使命完全一致。"
"我很高兴在这一关键时刻加入Silexion，"佩雷德教授说道。"公司的RNAi平台对于解决一些最具挑战性的肿瘤学指征具有巨大的潜力。我期待贡献我的专业知识，以帮助推进Silexion的创新管线，为患者创造有意义的影响。"
佩雷德教授的任命重申了Silexion在推动其RNAi平台和针对KRAS突变的下一代疗法方面对科学和战略卓越的承诺。他在临床开发和监管路径方面的丰富经验将为Silexion致力于为面临最具挑战性癌症的患者提供创新解决方案的使命贡献力量。佩雷德教授的任命也填补了当前的董事会空缺，确保Silexion继续符合纳斯达克的上市要求，包括拥有一个完整组成的审计委员会。
关于Amnon Peled教授
佩莱德教授担任耶路撒冷哈达萨医疗中心基因治疗研究所的主任，他的研究重点是细胞因子在造血干细胞生物学、炎症和癌症中的作用。在他28年的职业生涯中，他领导了关于趋化因子受体CXCR4的开创性研究，该受体是干细胞动员和癌症中的关键角色。佩莱德教授发表了超过120篇科学文献，并持有超过200项与干细胞生物学、免疫学和癌症相关的治疗应用专利和专利申请。
佩莱德教授对生物技术的贡献包括与多家以色列领先生物技术公司的紧密合作，如Biokine Therapeutics、BiolineRX (纳斯达克: BLRX)、Gamida Cell、KAHR Medical和AlonBio。他是Biokine Therapeutics、AlonBio和SakuraBio的创始人。在CXCR4拮抗剂BKT140/BL8040和Gamida Cell的Nk和脐带血干细胞扩展技术的开发中，他的领导力为多项FDA批准奠定了基础。佩莱德教授在魏兹曼科学学院获得了博士学位，并在哈佛医学院和千年制药公司进行了博士后研究。
关于Silexion Therapeutics
Silexion Therapeutics (纳斯达克: SLXN)是一家开创性的临床阶段肿瘤学聚焦的生物技术公司，开发创新的RNA干扰(RNAi)疗法以治疗由KRAS突变驱动的实体肿瘤，这是人类癌症中最常见的致癌驱动因子。该公司的第一代产品LODER在针对不可切除的胰腺癌的2期临床试验中显示出有希望的结果。Silexion还在推进其下一代siRNA候选药物SIL-204，旨在针对更广泛的KRAS突变，并在临床前研究中显示出显著的潜力。该公司始终致力于推动肿瘤学治疗创新的边界，重点改善难治性癌症患者的治疗结果。
